Publications by authors named "A Fyles"
Background: There are currently no molecular tests to identify individual breast cancers where radiotherapy (RT) offers no benefit. Profile for the Omission of Local Adjuvant Radiotherapy (POLAR) is a 16-gene molecular signature developed to identify low risk cancers where RT will not further reduce recurrence rates.
Methods: An individual participant data meta-analysis was performed in 623 cases of node-negative ER+/HER2-negative early breast cancer enrolled in three RT randomized trials for whom primary tumor material was available for analysis.
Clinical Outcomes of 3 Versus 4 Fractions of Magnetic Resonance Image-Guided Brachytherapy in Cervical Cancer.
Int J Radiat Oncol Biol Phys
November 2024
Purpose: Magnetic resonance image-guided brachytherapy is essential in the management of locally advanced cervical cancer. This study compares disease and toxicity outcomes in cervical cancer patients treated with 24 Gy/3 fractions (Fr) versus the conventional 28 Gy/4 Fr.
Methods And Materials: This retrospective study included 241 consecutive patients with International Federation of Gynecology and Obstetrics 2018 stage IB to IVA cervical cancer treated with definitive chemoradiation between April 2014 and March 2021.
Ki-67 is a nuclear protein associated with proliferation, and a strong potential biomarker in breast cancer, but is not routinely measured in current clinical management owing to a lack of standardization. Digital image analysis (DIA) is a promising technology that could allow high-throughput analysis and standardization. There is a dearth of data on the clinical reliability as well as intra- and interalgorithmic variability of different DIA methods.
View Article and Find Full Text PDFThe Ki-67 proliferation index (PI) guides treatment decisions in breast cancer but suffers from poor inter-rater reproducibility. Although AI tools have been designed for Ki-67 assessment, their impact on pathologists' work remains understudied. 90 international pathologists were recruited to assess the Ki-67 PI of ten breast cancer tissue microarrays with and without AI.
View Article and Find Full Text PDFArticle Synopsis
- - A new immune-based gene expression risk score was created to predict distant metastases (DM) in cervical cancer patients, based on RNA sequencing of tumor biopsies from 81 individuals before treatment.
- - The risk score, derived from 55 immune-related genes, was validated in additional patient cohorts and showed strong predictive ability for both DM and lower cause-specific survival, with higher scores linked to lower levels of immune cells in the tumor microenvironment.
- - The study emphasizes the relationship between high tumor mutational burden, a lack of immune cells in tumors (classified as "cold"), and the increased risk of metastatic recurrence, urging further validation of the risk score for clinical use.